28 October 2020>: Clinical Research
Need for Greater Attention to Joint Damage in Rhupus Patients: Results from an Ultrasound Study
Zhi-Xin Chen 123BCE* , Pei-Dan Yang 12CDE* , Min-Ying Liu 12BCE* , Ping-Fang Song 4EF , Qiang Xu 12AEFG*DOI: 10.12659/MSM.927104
Med Sci Monit 2020; 26:e927104
Table 3 Prednisone, DMARDs, and biologics used in rhupus patients and SLE with arthropathy patients.
Medication use | Rhupus | SLE with arthropathy | P value |
---|---|---|---|
Prednisone, n (%) | 5/10 (50.00%) | 31/33 (93.90%) | 0.001* |
Biological drugs used, n (%) | 2/10 (20.00%) | 0/33 (0.00%) | 0.009* |
MTX, n (%) | 6/10 (60.00%) | 12/33 (36.40%) | 0.275 |
HCQ, n (%) | 4/10 (40.00%) | 30/33 (90.10%) | 0.002* |
LEF, n (%) | 2/10 (20.00%) | 2/33 (6.00%) | 0.226 |
THH, n (%) | 6/10 (60.00%) | 8/33 (24.24%) | 0.055 |
MMF, n (%) | 1/10 (10.00%) | 4/33 (12.12%) | >0.999 |
CsA, n (%) | 0/10 (0.00%) | 2/33 (6.00%) | >0.999 |
CTX, n (%) | 0/10 (0.00%) | 4/33 (12.12%) | 0.558 |
MTX – methatrexate; HCQ – hydroxychloroquine; LEF – leflunomide; THH – tripterygium hypoglaucum hutch; MMF – mycophenolate mofetil; CsA – cyclosporine A;CTX – cyclophosphamide. * P |